Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics

Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics Deal

Related Keywords

United States ,Paris ,France General ,France ,Netherlands ,Amsterdam ,Noord Holland ,Carsten Linnemann ,Assia Mouhout ,Rachel Mears ,Arie Belldegrun ,Santa Monica ,Marion Bougeard ,Kite Pharma Inc ,Linkedin ,Allogene Therapeutics Inc ,Twitter ,Neogene Therapeutics Inc ,Astrazeneca ,Loncode Institute ,Netherlands Cancer Institute ,Jeito Capital ,Neogene Therapeutics ,Board Member ,Chief Executive Officer ,Ton Schumacher ,Principal Investigator ,Two River ,Kite Pharma ,Executive Chairman ,Allogene Therapeutics ,With Jeito ,Private Equity ,Vida Ventures ,Polaris Partners ,Strategic Communications Mary Jane Elliott ,Davide Salvi ,Jeito ,Capital ,Emonstrates ,European ,Iopharma ,Leadership ,First ,Exit ,Cquisition ,Neogene ,Herapeutics ,